市场趋势
短期 | 中期 | ||
行业 | Biotechnology (US) | 混合的 | 混合的 |
Biotechnology (全球的) | 混合的 | 混合的 | |
股票 | NuCana plc | 混合的 | 看跌 |
AIStockmoo 评分
0.8
分析师共识 | NA |
内部交易活动 | NA |
价格波动 | 0.5 |
技术平均移动指标 | 0.0 |
技术振荡指标 | 2.0 |
平均 | 0.83 |
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States. |
|
部门 | Healthcare |
行业 | Biotechnology |
内部持股比例 | 0.21% |
机构持股比例 | 11.72% |
所有权
姓名 | 日期 | 持有股份 |
---|---|---|
Glass Jacobson Investment Advisors Llc | 31 Dec 2024 | 15,000 |
Allsquare Wealth Management Llc | 31 Dec 2024 | 205 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合